Synergy Pharmaceuticals Inc. | Ownership
Companies that own Synergy Pharmaceuticals Inc.
The Vanguard Group, Inc.
20,301,649
8.19%
387,932
0%
06/30/2018
BlackRock Fund Advisors
20,257,257
8.17%
277,999
0%
06/30/2018
SSgA Funds Management, Inc.
12,698,842
5.12%
-7,197,018
0%
06/30/2018
Heights Capital Management, Inc.
11,760,726
4.74%
8,660,765
0.66%
06/30/2018
Nantahala Capital Management LLC
11,578,568
4.67%
0
1.62%
06/30/2018
Northern Trust Investments, Inc.
2,957,835
1.19%
24,816
0%
06/30/2018
Susquehanna Financial Group LLLP
2,429,670
0.98%
506,295
0.02%
06/30/2018
Geode Capital Management LLC
2,321,991
0.94%
286,942
0%
06/30/2018
Shigeta Yasumitsu (Investment Portfolio)
2,300,000
0.93%
300,000
0.42%
06/30/2018
JPMorgan Investment Management, Inc.
1,440,975
0.57%
-86,625
0%
06/30/2018
| Address |
420 Lexington Avenue
New York New York 10170
United States
|
|
Employees
|
- |
| Website |
http://www.synergypharma.com |
| Updated |
09/14/2018 |
| Synergy Pharmaceuticals, Inc. engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The company was founded by Kunwar Shailubhai on November 15, 2005 and is headquartered in New York, NY. |
